MRKR

Marker Therapeutics, Inc.

4.24 USD
-0.47 (-9.98%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Marker Therapeutics, Inc. stock is up 2.42% since 30 days ago. The next earnings date is Jul 9, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 51.85% of the previous 26 June’s closed higher than May.

About Marker Therapeutics, Inc.

Marker Therapeutics, Inc. engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors. It is also developing TPIV100/110 and TPIV200, which is in Phase 2 clinical trials for breast and ovarian cancers.